The mission of the Therapeutic Development Program (TDP) is to discover, validate and inhibit new molecular targets for the development of novel cancer therapeutics. The program encompasses target identification, as well as lead agent identification and subsequent optimization development through preclinical and early, "proof of principle," therapeutic trials that interrogate those new targets.
Program Leaders
Robert T. Dorr, Ph.D., R.Ph.
Michael A. Bookman, MD
Program Project Grant
1. Therapeutic Targeting of Hypoxic and Oxidative Stress (5P01 CA017094-33; P.I.: Robert Dorr, Ph.D.) (Renewed 2007)
E-mail this page